Charles Schwab’s Citius Pharmaceuticals CTXR Stock Holding History

Charles Schwab’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,043	Closed	-$38.1K	–	3497
2024 Q3	$38.1K	Hold	3,043	–	–	﹤0.01%	3441
2024 Q2	$44.4K	Sell	3,043 -11,237	-79%	-$201K	﹤0.01%	3520
2024 Q1	$320K	Hold	14,280	–	–	﹤0.01%	3163
2023 Q4	$270K	Hold	14,280	–	–	﹤0.01%	3235
2023 Q3	$244K	Hold	14,280	–	–	﹤0.01%	3249
2023 Q2	$428K	Buy	14,280 +11,237	+369%	+$370K	﹤0.01%	3125
2023 Q1	$89K	Hold	3,043	–	–	﹤0.01%	3266
2022 Q4	$60.1K	Hold	3,043	–	–	﹤0.01%	3326
2022 Q3	$93K	Hold	3,043	–	–	﹤0.01%	3229
2022 Q2	$70K	Sell	3,043 -11,071	-78%	-$304K	﹤0.01%	3334
2022 Q1	$632K	Buy	14,114 +2,763	+24%	+$109K	﹤0.01%	3032
2021 Q4	$438K	Hold	11,351	–	–	﹤0.01%	3188
2021 Q3	$577K	Hold	11,351	–	–	﹤0.01%	3097
2021 Q2	$988K	Buy	11,351 +9,630	+560%	+$579K	﹤0.01%	2938
2021 Q1	$77K	Buy	+1,721	New	+$68.5K	﹤0.01%	3401

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

Charles Schwab's CTXR Position: Q4 2024 in Review

Charles Schwab sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 3,043 shares — an estimated $38.1K sold.

Charles Schwab first reported a position in CTXR in Q1 2021 and held it in 15 quarters. The position peaked at $988K in Q2 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

Charles Schwab reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Charles Schwab sold 3,043 Citius Pharmaceuticals shares in Q4 2024, an estimated $38.1K.
Charles Schwab first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 15 quarters.
Charles Schwab's Citius Pharmaceuticals position peaked at $988K in Q2 2021.
30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.